Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin versus idarubicin in acute myeloid leukemia
PACTR202309818279236Phase 4Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of doxorubicin and idarubicin in acute myeloid leukemia (AML) (2 arms), sponsored by National Cancer Institute. Started Sep 2017; status: completed.
02
Drugs
doxorubicinidarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on PACTR202309818279236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202309818279236.